NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

$171.55

-2.30 (-1.32%)

(As of 09/22/2023 ET)

Compare

Today's Range: $169.85
▼
$174.51
50-Day Range: $173.85
▼
$211.65
52-Week Range: $169.85
▼
$242.97

Volume: 678,887 shs
Average Volume: 685,457 shs
Market Capitalization: $21.44 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $247.40

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.76 Rating Score
Upside/Downside: 44.2% Upside
$247.40 Price Target
Short Interest: Healthy
4.24% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.52
Upright™ Environmental Score
News Sentiment: 0.33
Based on 13 Articles This Week
Insider Trading: Selling Shares
$2.81 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.79) to ($3.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

124th out of 968 stocks

Pharmaceutical Preparations Industry

38th out of 445 stocks

4.4

Analyst's Opinion

Consensus Rating
Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $247.40, Alnylam Pharmaceuticals has a forecasted upside of 44.2% from its current price of $171.55.
Amount of Analyst Coverage
Alnylam Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.24% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.
Change versus previous month
Short interest in Alnylam Pharmaceuticals has recently decreased by 1.49%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Alnylam Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alnylam Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alnylam Pharmaceuticals is -1.52.

1.8

News and Social Media Coverage

News Sentiment
Alnylam Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Alnylam Pharmaceuticals this week, compared to 7 articles on an average week.
Search Interest
Only 9 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,806,347.00 in company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.
Percentage Held by Institutions
93.98% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.79) to ($3.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alnylam Pharmaceuticals is -19.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alnylam Pharmaceuticals is -19.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Price History

30 days | 90 days | 365 days | Advanced Chart

ALNY Stock News Headlines

September 7, 2023 | marketbeat.com

3 Stocks to Buy For the COVID Resurgence (ALNY)

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

September 19, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Reiterated by HC Wainwright

September 22, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 18, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts

September 18, 2023 | americanbankingnews.com

Q2 2024 EPS Estimates for Alnylam Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:ALNY)

September 16, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at Stifel Nicolaus

September 16, 2023 | americanbankingnews.com

Cantor Fitzgerald Reaffirms "Neutral" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

September 15, 2023 | msn.com

Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease

September 22, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

September 15, 2023 | msn.com

Alnylam stock falls after FDA panel questions drug's effectiveness

September 14, 2023 | msn.com

Alnylam’s RNA interference drug wins favour of FDA AdCom

September 14, 2023 | markets.businessinsider.com

Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects

September 13, 2023 | marketwatch.com

Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA

September 13, 2023 | markets.businessinsider.com

Alnylam Pharmaceuticals: FDA Committee To Review SNDA For Patisiran; Trading Halted

September 13, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Needham & Company LLC

September 13, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reiterated at Royal Bank of Canada

September 12, 2023 | markets.businessinsider.com

What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

September 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and ADC Therapeutics (ADCT)

September 11, 2023 | benzinga.com

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today

September 11, 2023 | bloomberg.com

FDA Casts Doubt on Alnylam Drug Trial Results for Expanded Usage

September 9, 2023 | seekingalpha.com

Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility

September 9, 2023 | reuters.com

Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial

September 8, 2023 | bizjournals.com

BBJ honors corporate philanthropy leaders at annual event

September 8, 2023 | finance.yahoo.com

Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More

September 8, 2023 | markets.businessinsider.com

Citi Remains a Buy on Ionis Pharmaceuticals (IONS)

September 7, 2023 | bizjournals.com

Alnylam supports Cambridge-area addiction recovery program

September 7, 2023 | news.yahoo.com

Alnylam hypertension drug meets main goal in mid-stage study

See More Headlines

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings: 8/03/2023
Today: 9/22/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ALNY
CUSIP: 02043Q10
CIK: 1178670
Web: www.alnylam.com
Phone: (617) 551-8200
Fax: 617-551-8101
Employees: 2,002
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $247.40
High Stock Price Forecast: $405.00
Low Stock Price Forecast: $143.00
Forecasted Upside/Downside: +43.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.76
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,131,160,000.00
Net Margins: -85.95%
Pretax Margin: -85.63%
Return on Equity: -1,287.80%
Return on Assets: -30.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.20
Quick Ratio: 3.07

Sales & Book Value

Annual Sales: $1.04 billion
Price / Sales: 20.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.29) per share
Price / Book: -133.52

Miscellaneous

Outstanding Shares: 125,000,000
Free Float: 123,251,000
Market Cap: $21.53 billion
Optionable: Optionable
Beta: 0.45

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Yvonne L. Greenstreet M.B.A. (Age 60)
MBA, MBChB, CEO & Director
Comp: $2.09M

Dr. Akshay K. Vaishnaw M.D. (Age 60)
Ph.D., Pres
Comp: $1.24M

Mr. Jeffrey V. Poulton M.B.A. (Age 55)
CFO & Exec. VP
Comp: $972.35k

Ms. Indrani M. Lall Franchini J.D. (Age 51)
Exec. VP, Chief Legal Officer & Sec.
Comp: $958.96k

Dr. Pushkal P. Garg M.D. (Age 55)
Chief Medical Officer and Exec. VP of Devel. & Medical Affairs
Comp: $1M

Mr. Timothy J. Maines
Chief Technical Operations & Quality Officer

Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
Sr. VP, Head of Research & Chief Scientific Officer

Ms. Christine Regan Lindenboom (Age 42)
Sr. VP of Investor Relations & Corp. Communications

Mr. Piyush Sharma J.D.
Chief Ethics & Compliance Officer

Mr. Mark Baglin
VP of Global Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?: 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.
What is Alnylam Pharmaceuticals' stock price forecast for 2023?: 21 analysts have issued twelve-month price targets for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $143.00 to $405.00. On average, they anticipate the company's share price to reach $247.40 in the next twelve months. This suggests a possible upside of 43.6% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.
How have ALNY shares performed in 2023?: Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. Since then, ALNY shares have decreased by 27.5% and is now trading at $172.24.
View the best growth stocks for 2023 here.
When is Alnylam Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ALNY earnings forecast.
How were Alnylam Pharmaceuticals' earnings last quarter?: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.72) by $0.49. The biopharmaceutical company had revenue of $318.75 million for the quarter, compared to analyst estimates of $331.73 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 1,287.80% and a negative net margin of 85.95%.
What ETFs hold Alnylam Pharmaceuticals' stock?: ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED).
What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?: Alnylam Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.44 billion.
What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?: 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).
What is Alnylam Pharmaceuticals' stock symbol?: Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
Who are Alnylam Pharmaceuticals' major shareholders?: Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital World Investors (13.20%), Baillie Gifford & Co. (6.74%), BlackRock Inc. (6.71%), State Street Corp (2.31%), Capital International Investors (2.30%) and Capital Research Global Investors (1.88%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.
How do I buy shares of Alnylam Pharmaceuticals?: Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alnylam Pharmaceuticals' stock price today?: One share of ALNY stock can currently be purchased for approximately $172.24.
How much money does Alnylam Pharmaceuticals make?: Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $21.53 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.61) on an earnings per share basis.
How many employees does Alnylam Pharmaceuticals have?: The company employs 2,002 workers across the globe.
How can I contact Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial